Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option

T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma—Implications for Adoptive Cell Therapy

(2018) Rikke Andersen et al.   Cancer Immunology Research

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma

(2018) John E. Mullinax et al.   Frontiers in Oncology

High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions

(2017) Stephen Marabondo et al.   Expert Opinion On Drug Safety

Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study

(2017) Smita S Chandran et al.   LANCET ONCOLOGY

Targeted agents and immunotherapies: optimizing outcomes in melanoma

(2017) Jason J. Luke et al.   Nature Reviews Clinical Oncology

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes

(2017) Marie-Andrée Forget et al.   Frontiers in Immunology

Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation

(2017) Sivan Seliktar-Ofir et al.   Frontiers in Immunology

Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

(2016) R. Andersen et al.   CLINICAL CANCER RESEARCH

A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma

(2016) Drew C. Deniger et al.   CLINICAL CANCER RESEARCH

Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy

(2016) Sander Kelderman et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma

(2016) Stephanie L. Goff et al.   JOURNAL OF CLINICAL ONCOLOGY

Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe – a systematic review of the literature

(2016) Fernanda Costa Svedman et al.   Clinical Epidemiology

Toxicities Associated With Adoptive T-Cell Transfer for Cancer

(2015) James C. Yang   CANCER JOURNAL

Tumor-Infiltrating Lymphocyte Therapy

(2015) Laszlo G. Radvanyi   CANCER JOURNAL

Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells

(2015) Sanja Stevanović et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma

(2015) Joal D Beane et al.   MOLECULAR THERAPY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor

(2014) Marco Donia et al.   CYTOTHERAPY

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab

(2014) Ahmad A. Tarhini et al.   PLoS One

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

(2014) E. Tran et al.   SCIENCE

Early Cost-Effectiveness Modeling for Tumor Infiltrating Lymphocytes (TIL) -Treatment Versus Ipilimumab in Metastatic Melanoma Patients

(2014) V.P. Retèl et al.   VALUE IN HEALTH

Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival

(2014) Amir Khammari et al.   Journal of Immunology Research

Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

(2013) M. J. Besser et al.   CLINICAL CANCER RESEARCH

CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor

(2013) Q. Ye et al.   CLINICAL CANCER RESEARCH

Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma

(2013) Mark E. Dudley et al.   JOURNAL OF CLINICAL ONCOLOGY

Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer

(2012) X. Yao et al.   BLOOD

Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma

(2012) Richard Wu et al.   CANCER JOURNAL

Exploiting the Mutanome for Tumor Vaccination

(2012) J. C. Castle et al.   CANCER RESEARCH

Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

(2012) L. G. Radvanyi et al.   CLINICAL CANCER RESEARCH

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

(2012) Eva Ellebaek et al.   Journal of Translational Medicine

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

(2012) Hirokazu Matsushita et al.   NATURE

TIL therapy broadens the tumor-reactive CD8+T cell compartment in melanoma patients

(2012) Pia Kvistborg et al.   OncoImmunology

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

(2011) S. A. Rosenberg et al.   CLINICAL CANCER RESEARCH

Establishment and Large-scale Expansion of Minimally cultured “Young” Tumor Infiltrating Lymphocytes for Adoptive Transfer Therapy

(2011) Orit Itzhaki et al.   JOURNAL OF IMMUNOTHERAPY

CD8+ Enriched "Young" Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma

(2010) M. E. Dudley et al.   CLINICAL CANCER RESEARCH

Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells

(2010) Takashi Inozume et al.   JOURNAL OF IMMUNOTHERAPY

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

(2009) L. A. Johnson et al.   BLOOD

Ocular and Systemic Autoimmunity after Successful Tumor-Infiltrating Lymphocyte Immunotherapy for Recurrent, Metastatic Melanoma

(2009) Steven Yeh et al.   OPHTHALMOLOGY

IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes

(2008) S. Kaneko et al.   BLOOD

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

(2008) Mark E. Dudley et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy

(2008) Khoi Q. Tran et al.   JOURNAL OF IMMUNOTHERAPY

The Biology of Interleukin-2

(2007) Thomas R. Malek   Annual Review of Immunology